测量子宫内膜异位症女性的健康相关生活质量:比较子宫内膜异位症健康概况-5(EHP-5)与EuroQol-5D(EQ-5D)的测量学特性
前瞻性观察研究纳入2个法国三级中心的253例子宫内膜异位症女性,在治疗前和治疗后12个月填写EHP-5与EQ-5D。两种量表反应性均优良,EHP-5在区分能力上优于EQ-5D。
要点
- EHP-5与EQ-5D反应性均优良且相当,效应量分别为0.81与0.95。
- EHP-5在9项假设中的3项区分能力显著优于EQ-5D。
- 作者认为EHP-5是日常实践和临床研究中评估生活质量的简便有效工具。
核心结论
- EHP-5与EQ-5D反应性均优良,但EHP-5测量健康相关生活质量(HrQoL)的区分能力优于EQ-5D。
- 作者认为EHP-5是日常实践中评估生活质量的简便、有效且可靠的量具,也可作为评估治疗疗效的临床研究的主要结局指标。
研究设计与样本
- 前瞻性观察性研究,2012年1月1日至2013年12月31日在2个法国三级中心纳入253例经证实、正在接受药物或手术治疗的连续子宫内膜异位症女性。
- 纳入18岁以上、因持续至少3个月疼痛症状或不孕就诊、经组织学或影像学证实子宫内膜异位症的女性。
- 受试者在治疗前(T0)和治疗后12个月(T1)填写两种量表。
主要发现
- T0时216名女性完整填写全部问卷,T1时为133名(61.6%)。
- 两种量表对患者症状均有良好区分能力,EHP-5在9项假设中的3项显著优于EQ-5D。
- 痛经强度(视觉模拟量表)差异最大:EHP-5的Cohen's d效应量ES=0.86 95%CI(0.54-1.17),EQ-5D为ES=0.48 95%CI(0.16-0.79)。
- 按子宫内膜异位症特征分亚组,EHP-5与EQ-5D评分均无差异。
- 总体反应性优良且两量表相当:EHP-5 ES=0.81 95%CI(0.56-1.56),EQ-5D ES=0.95 95%CI(0.68-1.20)。
关键数值与推荐
- EHP-5在9项预设假设中3项区分能力显著优于EQ-5D。
- 痛经强度(视觉模拟量表)效应量:EHP-5 ES=0.86 95%CI(0.54-1.17) vs EQ-5D ES=0.48 95%CI(0.16-0.79)。
- 总体反应性:EHP-5 ES=0.81 95%CI(0.56-1.56) vs EQ-5D ES=0.95 95%CI(0.68-1.20)。
- 药物治疗亚组反应性:EHP-5 ES=0.93 95%CI(0.07-1.70) vs EQ-5D ES=0.73 95%CI(-0.06-1.47)。
临床怎么用
- 作者认为EHP-5是日常实践中评估生活质量的简便、有效且可靠的量具,也可用于临床研究评估治疗疗效并提供主要结局。
局限性
- 研究人群为有症状且以重型为主的子宫内膜异位症患者,可能存在谱偏倚。
- 药物治疗时反应性评估基于少量患者,限制了两量表在该亚组差异的解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Which of the Endometriosis Health Profile-5 (EHP-5) and the EuroQol-5D (EQ-5D) is the most efficient to assess quality of life in women suffering from endometriosis? SUMMARY ANSWER: Although EHP-5 and EQ-5D instruments had an excellent responsiveness, EHP-5 has a better discriminative ability than EQ-5 to measure health-related quality of life (HrQoL). WHAT IS KNOWN ALREADY: Proper measurement of HrQoL is important in endometriosis. While many quality of life instruments are available, few have been completely validated in endometriosis. The EHP-5 and the EQ-5D are short and practical scales, which may be useful. Literature is lacking to determine which one is the most suitable in clinical practice or in clinical research. STUDY DESIGN, SIZE, DURATION: This prospective and observational study conducted between 1 January 2012 and 31 December 2013 included a total of 253 consecutive women with proven endometriosis, undergoing medical or surgical treatment, in 2 French tertiary care centers. PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Women over 18 years consulting for painful symptoms of at least 3 months' duration or for infertility, with endometriosis proven histologically or radiologically, were requested to fill in the 2 scales before (T0) and 12 months after treatment (T1). Construct validity consisted in testing presupposed relationships between the scales and the characteristics of the patients or the endometriosis. Responsiveness to change was calculated for all patients and in each treatment group. Effect sizes were used according to Cohen's d method. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 216 women filled in completely all the questionnaires at T0 and 133 (61.6%) at T1. EHP-5 and EQ-5D had good discriminative abilities regarding the patients' symptoms, with significant superiority of EHP-5 concerning three of the nine hypotheses. The largest difference was that calculated for the 'intensity of dysmenorrhea' using the Visual Analogic Scale, with respectively effect size from Cohen's d (ES) = 0.86 95% CI (0.54-1.17) for EHP-5 versus 0.48 95% CI (0.16-0.79) for EQ-5D. There were no differences in EHP-5 or in EQ-5D scores between subgroups according to the characteristics of endometriosis. Overall responsiveness was excellent and equivalent for EHP-5 and for EQ-5D, with, respectively, ES = 0.81 95% CI (0.56-1.56) versus ES = 0.95 95% CI (0.68-1.20). In subgroup analyses, EHP-5 was responsive in case of medical treatment with ES = 0.93 95% CI (0.07-1.70), whereas EQ-5D was not, ES = 0.73 95% CI (-0.06-1.47). LIMITATIONS, REASONS FOR CAUTION: Our study population included patients with symptomatic and mainly severe forms of endometriosis, which may suggest a spectrum bias. The evaluation of responsiveness in case of medical treatment was based on a small number of patients, which limits the interpretation of the difference found between the two scales in this subgroup. WIDER IMPLICATIONS OF THE FINDINGS: EHP-5 is a simple, efficient and valid tool for evaluating quality of life in daily practice and also valuable to provide a primary outcome in clinical studies evaluating treatment efficacy. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by the Direction à la Recherche Clinique et à l'Innovation of Versailles, France. The authors have no conflicts of interest. TRIAL REGISTER NUMBER: None.
引用
- Aubry G, Panel P, Thiollier G, et al. Measuring health-related quality of life in women with endometriosis: comparing the clinimetric properties of the Endometriosis Health Profile-5 (EHP-5) and the EuroQol-5D (EQ-5D). Hum Reprod. 2017. PMID: 28383700. doi:10.1093/humrep/dex057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。